A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients With Homozygous Familial Hypercholesterolemia (HoFH) in India
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions
- Sponsors Amgen
- 04 Dec 2019 Status changed from active, no longer recruiting to completed.
- 30 Aug 2019 Planned End Date changed from 20 Sep 2019 to 22 Nov 2019.
- 30 Aug 2019 Planned primary completion date changed from 20 Sep 2019 to 22 Nov 2019.